03 Feb 2021 – Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Destiny Pharma Announces
Brazilian Patent Granted for XF-73 nasal gel preventing post-surgical infections

Brighton, United Kingdom – 3rd February 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that Brazil’s Industrial Property Office has issued a notice of allowance that will now lead to the final approval in March of the Company’s patent application (Brazilian Patent Application no. PI 0512563-4) in relation to XF-73.

Neil Clark, Chief Executive Officer of Destiny Pharma, said: “We are very pleased to obtain this additional patent award (PI 0512563-4) from Brazil’s Industrial Property Office. We now have 84 issued patents from three patent families related to our XF platform that will provide strong protection to our XF-73 nasal gel product, alongside standard market exclusivity awards, in all major territories.

We recently completed enrollment in our Phase 2b clinical trial testing XF-73 nasal gel as a novel product preventing the incidence of post-surgical infections such as MRSA. We are now looking forward to announcing the full results of this study towards the end of March 2021 and planning the Phase 3 clinical programme. There is also a significant commercial opportunity for XF-73 in the hospital setting which we estimate could generate peak annual product sales of $1 billion in the US alone.”

XF-73 is a first-in-class drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of postsurgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and
increased healthcare costs in the hospital setting. It has been awarded both qualifying infectious disease product (QIDP) and Fast Track status by the US FDA.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440

Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 203 174 1789

finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of postsurgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit https://www.destinypharma.com